Technical Capabilities

PrecisemAb Technical Service Platform

At Precisemab, our innovative Antibody Lock Technology Platform enables comprehensive services spanning from protein design and production to functional validation and in vivo pharmacological studies.Our goal is to support partners in accelerating antibody drug development with rigorous experimental design, high-quality data, and scientifically validated results to strengthen preclinical research and translational success.
Design

Design

Protein Drug Concept and Molecular Design

Protein and Gene Design
Design and construct DNA sequences and expression vectors for antibodies, recombinant proteins, or cytokines.
Perform sequence modification, site-directed mutagenesis, and tag insertion (e.g., His-tag) using PCR-based techniques.
Computer Simulation and Molecular Modeling
Develop selectively activatable Lock antibodies using structure-based design.
Conduct humanization of animal-derived antibodies.
Optimize antibody–antigen affinity through computational modeling and molecular dynamics analysis.
Human Tumor and Adjacent Tissue Repository
Prepare cryosections preserving antigen or molecular integrity for histological assays.
Perform IHZ protease activity assays to assess enzyme profiles in tumor tissues.
Conduct biomarker profiling using IF/IHC to evaluate antigen expression and binding characteristics.
Production Icon

Production

Stable Cell Line Development and Protein Production

Stable Cell Line Establishment
Generate antigen-expressing stable cell lines using lentiviral transduction for consistent, long-term protein production.
Protein Expression and Purification
Transfect high-yield mammalian cells for recombinant protein expression.
Purify target proteins using affinity chromatography (Protein A/G or Ni⁺ beads).
In Vitro Icon

In Vitro

Protein Characterization and Functional Validation

Binding Affinity and Interaction Analysis
Measure binding kinetics (kon/koff, KD) via SPR.
Conduct ELISA (direct, indirect, competitive formats).
Analyze cell binding activity using flow cytometry.
Evaluate tissue binding through IHC/IF using normal and tumor tissue samples.
Assess protease-dependent antibody cleavage via Western blot.
Flow Cytometry Applications
Quantify antibody–cell binding affinity and internalization efficiency.
Perform cell sorting (FACS) and compare antigen expression before and after treatment.
 Functional Assays
Conduct cytotoxicity assays (CDC, ADCC, LDH assay).
Perform growth inhibition assays using ATPlite for tumor cell proliferation analysis.
Tissue Binding and Imaging
Stain CDX/PDX tumor sections with IHC/IF for spatial localization.
Perform confocal microscopy for co-localization and internalization imaging (including live-cell observation).
In Vivo Icon

In Vivo

Animal Modeling and Pharmacological Validation

Tumor and Disease Model Establishment
Establish PDX, CDX, and orthotopic models (e.g., colorectal cancer).
Utilize humanized immune system mice (human PBMC engraftment).
Develop CIA (Rheumatoid arthritis) autoimmune disease models.
Efficacy and Mechanistic Studies
Assess protease activity in tumor lesions using IHZ assays.
Evaluate in vivo activation of Lock antibodies.
Measure therapeutic efficacy through IV/IP dosing, tumor volume monitoring, and survival analysis.
Monitor safety indicators such as body weight, behavior, and temperature.
Immunological and Molecular Assessments
Analyze cytokine release and immune cell composition.
Quantify tumor targeting and biodistribution using labeled antibodies.
Pharmacokinetics and Imaging Analysis
Determine PK parameters including half-life, AUC, Cmax, and clearance.
Conduct biodistribution studies using fluorescent or radiolabeled tracers.
Utilize IVIS imaging to visualize tumor growth, drug distribution, and real-time pharmacodynamics.